Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997042 | 0.81 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2CYP2C19GAA | |
| SCHEMBL23479951 | 0.77 | NPC1 (0.46) | NPC1RAB9APPARGSMN1; SMN2CYP2C19 | |
| SCHEMBL13948652 | 0.73 | RAB9A (0.48) | NPC1RAB9ASMN1; SMN2CYP2C19GAA | |
| SCHEMBL10044413 | 0.73 | PTGS2 (0.53) | SMN1; SMN2CYP2C19LMNAALDH1A1CYP1A2 | |
| SCHEMBL11612842 | 0.72 | KMT2A (0.52) | NPC1RAB9ASMN1; SMN2CYP2C19GAA | |
| SCHEMBL11615915 | 0.70 | KMT2A (0.52) | NPC1RAB9ASMN1; SMN2CYP2C19GAA | |
| SCHEMBL16832297 | 0.70 | KDM4E (0.56) | NPC1RAB9ASMN1; SMN2CYP2C19GAA | |
| SCHEMBL24803365 | 0.69 | KDM4E (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL17137836 | 0.69 | CYP1A2 (0.46) | NPC1RAB9ASMN1; SMN2CYP2C19GAA | |
| SCHEMBL16832401 | 0.68 | SMN1; SMN2 (0.58) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | NPC1 2024/4885RAB9A 2641/4885PPARG 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.